Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryan A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Saad A, et al. Among authors: reshef r. Biol Blood Marrow Transplant. 2019 Sep;25(9):1875-1883. doi: 10.1016/j.bbmt.2019.05.007. Epub 2019 May 11. Biol Blood Marrow Transplant. 2019. PMID: 31085303 Free PMC article. Clinical Trial.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR. Hardy NM, et al. Among authors: reshef r. Blood. 2012 Mar 22;119(12):2956-9. doi: 10.1182/blood-2011-09-378398. Epub 2012 Jan 30. Blood. 2012. PMID: 22289893 Free PMC article. Clinical Trial.
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT.
Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. Tizon R, et al. Among authors: reshef r. Bone Marrow Transplant. 2012 Oct;47(10):1332-7. doi: 10.1038/bmt.2011.260. Epub 2012 Feb 6. Bone Marrow Transplant. 2012. PMID: 22307018 Clinical Trial.
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC. Kumar AJ, et al. Among authors: reshef r. Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28. Biol Blood Marrow Transplant. 2013. PMID: 23635453 Free article.
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.
Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL. Reshef R, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10. Biol Blood Marrow Transplant. 2014. PMID: 25016197 Free PMC article.
Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.
Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM. Bagley SJ, et al. Among authors: reshef r. Biol Blood Marrow Transplant. 2015 Apr;21(4):768-71. doi: 10.1016/j.bbmt.2014.12.005. Epub 2014 Dec 24. Biol Blood Marrow Transplant. 2015. PMID: 25543093 Free article.
Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.
Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Goyal SD, et al. Among authors: reshef r. Bone Marrow Transplant. 2015 Aug;50(8):1057-62. doi: 10.1038/bmt.2015.82. Epub 2015 Apr 27. Bone Marrow Transplant. 2015. PMID: 25915806 Free PMC article.
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.
Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. Urbano-Ispizua A, et al. Among authors: reshef r. Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. doi: 10.1016/j.bbmt.2015.05.010. Epub 2015 May 15. Biol Blood Marrow Transplant. 2015. PMID: 25981509 Free PMC article.
196 results